Cafepharma Today

May 14 2025 - AbbVie pays ADARx $335M cash for next-gen siRNA options
AbbVie pays ADARx $335M cash for next-gen siRNA options
Novo Nordisk inks $2.2B deal for Septerna's preclinical obesity programs
Roche reports final overall survival outcomes from breast cancer treatment trial
GSK buys phase III–ready liver drug in potential $2B deal to play in MASH arena
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

New Drug Applications Approval for Five New Products in Japan
The Financial
Saturday, April 17, 2010 - 1:03pm
tags:
Japan, Nesina, type 2 diabetes, Metact, Unisa, hypertension, Rozerem, insomnia, Vectibix, cancer
Affymax and Takeda Report Phase 2 Analyses of Hematide/peginesatide in Hemodialysis Patients
PharmaLive
Saturday, April 17, 2010 - 12:58pm
tags:
Affymax, Takeda, Hematide/peginesatide, dialysis
Impax Labs amends co-promotion pact with Wyeth for Lyrica
Pharmabiz
Saturday, April 17, 2010 - 12:56pm
tags:
Impax Labs, Wyeth, Lyrica
Quebec, Ontario biotech strategy urged
Montreal Gazette, Canada
Saturday, April 17, 2010 - 12:55pm
tags:
biotech
Novartis initiates second phase-I trial for oral PTH1-34 to treat postmenopausal osteoporosis
Pharmabiz
Saturday, April 17, 2010 - 12:53pm
tags:
Novartis, Emisphere, Eligen Technology, PTH1-34, osteoporosis
US Court favours Par Pharma in Zegerid litigation case
Pharmabiz
Saturday, April 17, 2010 - 12:52pm
tags:
Par Pharmaceutical, Zegrid
RegeneRx Biopharmaceuticals Announces Proposed Public Offering
MarketWatch
Saturday, April 17, 2010 - 12:50pm
tags:
RegeneRx, IPOs
FDA approves BioAlliance Pharma's Oravig for OPC
The Medical News
Saturday, April 17, 2010 - 12:49pm
tags:
BioAlliance, Oravig, oropharyngeal candidiasis
Lawyer Can Sue for Profits From Use of Thalidomide as a Cancer Treatment
law.com
Saturday, April 17, 2010 - 12:41pm
tags:
legal, thalidomide, Celgene
Earnings Preview: Analysts eye Lilly future sales
Yahoo/AP
Saturday, April 17, 2010 - 12:37pm
tags:
Eli Lilly, earnings
It'll Be a Blockbuster! High Fives All Around, Right?
Motley Fool
Saturday, April 17, 2010 - 12:36pm
tags:
drug development, Sanofi, lixisenatide
Bristol-Myers Squibb to Post Select Investigational Compound Data Updates on Company Website
Yahoo/BusinessWire
Saturday, April 17, 2010 - 12:25pm
tags:
Bristol-Myers Squibb
FDA Approves Tarceva as a Maintenance Therapy for Advanced Non-Small Cell Lung Cancer
Yahoo/BusinessWire
Saturday, April 17, 2010 - 12:23pm
tags:
Tarceva, OSI Pharmaceuticals, non-small cell lung cancer, SATURN
Biotech IPOs On The Mend?
Yahoo/Investor's Business Daily
Saturday, April 17, 2010 - 12:21pm
tags:
biotech, IPOs
EntreMed Raises Additional $3 Million to Further Support Clinical Development of ENMD-2076 in Ovarian Cancer
Yahoo/PR NewsWire
Saturday, April 17, 2010 - 12:20pm
tags:
EntreMed, ENMD-2076, Aurora A/angiogenic kinase inhibitor, ovarian cancer
Molecular Insight falls as debt talks continue
Yahoo/AP
Saturday, April 17, 2010 - 12:17pm
tags:
Molecular Insight, debt
GeoVax Labs Announces Reverse Stock Split; Applies for Listing on NASDAQ
Yahoo/PR NewsWire
Saturday, April 17, 2010 - 12:15pm
tags:
GeoVax Labs
AEterna shares fall; Inspire, Rexahn rally
MarketWatch
Saturday, April 17, 2010 - 12:13pm
tags:
Aeterna Zentaris, Rexahn
What’s Ahead for Biotech Earnings
Minyanville
Saturday, April 17, 2010 - 12:11pm
tags:
biotech, earnings, Amylin, Gilead Sciences, Biogen Idec, Amgen, Genzyme
Patients Scramble for Relief in Face of Genzyme Drug Shortage
Wall St Journal
Saturday, April 17, 2010 - 12:10pm
tags:
Genzyme, Gaucher disease, Cerezyme, Fabrazyme, Fabry's disease

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline
The GLP-1 Saga Continues, And How
In the Pipeline
Defluorination is Happening Inside You Right Now
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.